1. Home
  2. TYRA vs NVGS Comparison

TYRA vs NVGS Comparison

Compare TYRA & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

SELL

Current Price

$19.70

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Logo Navigator Holdings Ltd. (Marshall Islands)

NVGS

Navigator Holdings Ltd. (Marshall Islands)

SELL

Current Price

$20.80

Market Cap

1.5B

ML Signal

SELL

Company Overview

Basic Information
Metric
TYRA
NVGS
Founded
2018
1997
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
TYRA
NVGS
Price
$19.70
$20.80
Analyst Decision
Strong Buy
Buy
Analyst Count
15
6
Target Price
★ $47.45
$26.08
AVG Volume (30 Days)
★ 577.7K
377.0K
Earning Date
11-10-2026
11-03-2026
Dividend Yield
N/A
★ 1.52%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$13.06
Revenue Growth
N/A
N/A
52 Week Low
$15.94
$17.12
52 Week High
$40.65
$25.48

Technical Indicators

Market Signals
Indicator
TYRA
NVGS
Relative Strength Index (RSI) 41.01 44.25
Support Level $18.46 $19.84
Resistance Level $22.69 $22.69
Average True Range (ATR) 1.19 0.71
MACD -0.10 0.12
Stochastic Oscillator 12.33 55.70

Price Performance

Historical Comparison
TYRA
NVGS

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About NVGS Navigator Holdings Ltd. (Marshall Islands)

Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.

Share on Social Networks: